Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Vivo Bio Tech Ltd Fundamentals

Market Cap
₹ 64.35 Cr
P/E Ratio (TTM)
16.67
P/B Ratio
1.23
Debt to Equity
1.31
ROE
5.31
EPS (TTM)
2.59
Dividend Yield
0.00 %
Book Value
35.12

Click here to know more about Fundamentals

Vivo Bio Tech Ltd Financials

Vivo Bio Tech Ltd Financials

Vivo Bio Tech Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 42.08 % 42.08 % 42.08 % 42.08 %
Others 32.57 % 34.40 % 34.49 % 34.06 %
Retail 25.35 % 23.52 % 23.43 % 23.86 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

42.08%

Others

32.57%

Retail

25.35%

Mutual Funds

0.00%

FII

0.00%

Promoters

42.08%

Others

34.40%

Retail

23.52%

Mutual Funds

0.00%

FII

0.00%

Promoters

42.08%

Others

34.49%

Retail

23.43%

Mutual Funds

0.00%

FII

0.00%

Promoters

42.08%

Others

34.06%

Retail

23.86%

Mutual Funds

0.00%

FII

0.00%

Resistance and Support

₹43.11

PIVOT

resistance-arrow
Resistance
First Resistance₹44.220
Second Resistance₹45.260
Third Resistance₹46.370
support-arrow
Support
First Support₹42.070
Second Support₹40.960
Third Support₹39.920

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day13,95510,85477.78
Week13,9558,8000.00
1 Month13,95520,0150.00
6 Months5,982,6874,069,25569.92

About Vivo Bio Tech Ltd

Vivo Bio Tech is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities. The Biologic Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins. In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists. The In-vivo Services group at Vivo Bio Tech provides both non-regulatory and regulatory IND enabling preclinical development services. We are capable of screening & evaluating molecules for various pharmacological & therapeutic properties. Specifically for oncology, our scientists can provide design & development of xenograft models for evaluation of anti-cancer agents. Further, our scientists can customize in-vivo DMPK studies to help profile your drug candidate in both rodent and non-rodent animal models. Vivo Bio has partnered with Taconic for sourcing foundation and expansion colonies of the animal models and have started in-house breeding of Specific Pathogen Free rodents.

Managing Director

1987

Founded

NA

NSE Symbol

NA

Vivo Bio Tech Ltd Management

NameDesignation
Kalyan Ram MangipudiWhole-time Director
Kunasingam Sittampalam Director
Kalyan Ram Director
Alangudi SankaranarayananWhole-time Director
Allagudi Sankanarayanan CEO & Whole Time Director
K SunderChairman & Independent Directo
Hariharan RavindranIndependent Director
V Narasiah Director
Sri Kalyan Whole-time Director
Kunda KalpanaIndependent Director
Madhusudhana Reddy Company Secretary
Karopadi Shivanand NayakDirector
K Sri KalyanWhole Time Director & CFO
Shyam Sunder TipparajuAdditional Director

Vivo Bio Tech Ltd News

Vivo Bio Tech schedules board meeting
On 20 May 2024
Vivo Bio Tech consolidated net profit rises 780.00% in the December 2023 quarter
Sales decline 5.10% to Rs 12.85 crore
Vivo Bio Tech to convene board meeting
On 12 February 2024
Vivo Bio Tech announces board meeting date
On 14 November 2023
Vivo Bio Tech to convene board meeting
On 21 September 2023
Vivo Bio Tech to conduct AGM
On 30 September 2023
Vivo Bio Tech consolidated net profit declines 56.25% in the June 2023 quarter
Sales rise 2.84% to Rs 11.58 crore
Vivo Bio Tech to declare Quarterly Result
On 7 August 2023
Vivo Bio Tech to table results
On 30 May 2023
Vivo Bio Tech consolidated net profit declines 89.05% in the December 2022 quarter
Sales rise 4.80% to Rs 13.54 crore

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 367554.12 Cr
₹ 1,531.90
(0.03 %)
89.16
Cipla Ltd₹ 113362.29 Cr
₹ 1,404.05
(0.36 %)
30.52
Zydus Lifesciences Ltd₹ 111083.2 Cr
₹ 1,103.95
(5.00 %)
41.35
Divis Laboratories Ltd₹ 104302.61 Cr
₹ 3,929.00
(0.47 %)
76.42
Dr Reddys Laboratories Ltd₹ 96948.1 Cr
₹ 5,811.60
(0.21 %)
22.34

Vivo Bio Tech Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Vivo Bio Tech Ltd shares in BlinkX

Vivo Bio Tech Ltd's P/E ratio is 16.67 times as of May 18, 2024 at 04:00 PM.

Vivo Bio Tech Ltd's most recent financial reports indicate a price-to-book ratio of 1.23, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Vivo Bio Tech Ltd's market is 64 Cr as on May 18, 2024 at 04:00 PM.

The current financial records of Vivo Bio Tech Ltd show a 5.31% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Vivo Bio Tech Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Vivo Bio Tech Ltd stands at 42.08%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.